| US 7,455,837 B2 | ||
| Compositions and methods for the diagnosis and treatment of sepsis | ||
| Renfeng Guo, Ann Arbor, Mich. (US); Niels C. Riedemann, Hannover (Germany); Peter A. Ward, Ann Arbor, Mich. (US); Markus Huber-Lang, Blaustein-Arnegg (Germany); and J. Vidya Sarma, Ann Arbor, Mich. (US) | ||
| Assigned to The Regents of the University of Michigan, Ann Arbor, Mich. (US) | ||
| Filed on Nov. 05, 2003, as Appl. No. 10/701,871. | ||
| Claims priority of provisional application 60/423759, filed on Nov. 05, 2002. | ||
| Prior Publication US 2004/0166541 A1, Aug. 26, 2004 | ||
| Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 38/16 (2006.01) | ||
| U.S. Cl. 424—143.1 [424/139.1; 514/8; 514/921] | 2 Claims |
| 1. A method of treating sepsis in a subject suffering from sepsis, wherein said sepsis is selected from the group consisting
of sepsis due to gram-positive bacteremia and sepsis due to gram-negative bacteremia comprising
(a) providing a reagent capable of blocking C5a receptor, wherein said reagent is a monoclonal antibody that specifically
binds to said C5a receptor; and
(b) administering said reagent to said subject, wherein said subject's survival is prolonged.
|